Navigation Links
Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
Date:9/30/2010

FREDERICK, Md., Sept. 30 /PRNewswire/ -- Vaccinogen, Inc. has appointed veteran biotechnology executive Michael L. Kranda as President and Chief Executive Officer to guide it through its next stage of growth.

"The timing couldn't be better – as the company proceeds to finance and launch our pivotal Phase III clinical trial," said Michael G. Hanna, Jr., Ph.D., Vaccinogen's Founder & Chairman and inventor of the company's unique cancer-fighting vaccine OncoVAX®.

Co-founder and COO Andrew L. Tussing said Mr. Kranda was the clear choice to head the break-through biopharmaceutical company.  "He has the vision and experience to lead us through this important phase in our growth," Mr. Tussing said.

"I'm excited about OncoVAX®'s potential to save lives and Vaccinogen's role as a pioneer in using autologous vaccines to combat cancer," said Mr. Kranda.  "I look forward to building on the OncoVAX® technology to create an important and leading company in the cancer vaccine arena."

Literally Turning Cancer on Itself™, Vaccinogen works to harness the body's immune system to prevent the recurrence of cancer in patients recovering from the disease.

Mr. Kranda brings to Vaccinogen more than two decades of experience developing biotechnology platforms, products and companies. He sits on the board of directors of several companies including PTC Therapeutics.

Previously, Mr. Kranda served as the CEO, President and Director of Anesiva. Prior to joining Anesiva, Mr. Kranda was Managing Director of Vulcan Capital, Paul Allen's investment arm, where he led the life science venture investments team.  Mr. Kranda also served as CEO of Oxford GlycoSciences, and led their listings on the LSE and NASDAQ exchanges and prior to that was President and COO of Immunex (now Amgen).

Mr. Kranda holds a BA and an MBA from the University of Washington School of Business.

About OncoVAX®OncoVAX® transforms the body's immune response to prevent the return of the disease after surgery. As published in the journal Human Vaccines, Stage II OncoVAX® patients achieve "a 57.1% relative risk reduction in the recurrence of colon cancer" vs. the control patients in a previous clinical trial.

About VaccinogenVaccinogen develops and commercializes cancer vaccines and other immunotherapeutic products – Turning Cancer on Itself™. Based in Frederick, MD, the Company has a portfolio of product candidates for the treatment of cancer in various stages of clinical development.

www.vaccinogeninc.comContact:Andrew L. TussingVaccinogenatussing@vaccinogeninc.com301-668-8400
'/>"/>

SOURCE Vaccinogen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. RF Technologies® Names Mark Harwood New President
2. FierceBiotech Names iPierian as One of the Fierce 15 Biotech Companies of 2010
3. DNASequencing.com and a Portfolio of 318 Genetic Domain Names to be Auctioned Off at Epik.com Domain Development Conference
4. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
5. Protalix BioTherapeutics Names Tzvi Palash Chief Operating Officer
6. Signum Biosciences Names Braham Shroot as Chief Executive Officer
7. Diversity Publication Names University Hospitals One of Top Hospital Systems in the Nation
8. Talecris Names John Perkins as Executive Vice President, Global Commercial Operations
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. Transgenomic Names Dr. Katherine Richardson Technical Director for Laboratory Services
11. Thomson Reuters Names the Worlds Hottest Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), ... for operable and inoperable solid tumor cancers, announced today ... of NW Bio, will present at the Phacilitate Immunotherapy ... Hyatt Regency Hotel in Miami, Florida ... entitled "New Therapeutic Approaches – Expanding the Reach of ...
(Date:1/19/2017)... 18, 2017 BD (Becton, Dickinson and Company) (NYSE: ... it will host a live webcast of its Annual Meeting of ... The webcast can be accessed from the BD corporate ... Tuesday, January 31, 2017. ... About BD BD is a global medical technology ...
(Date:1/18/2017)... According to a new market research report "In situ Hybridization Market by Technique ... Diagnostic Laboratories, Academic and Research Institutions) - Global Forecast to 2021" published by ... USD 557.1 Million in 2016, growing at a CAGR of 5.8%. ... ... MarketsandMarkets Logo ...
(Date:1/18/2017)... Applied BioMath ( www.appliedbiomath.com ), the ... and development, today announced that Dr. John ... Applied BioMath, will present at the next Boston ... on Thursday January 19, 2017 at the Broad ... Dr. Burke,s talk "Quantitative Modeling and Simulation Approaches: ...
Breaking Biology Technology:
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
(Date:1/12/2017)... , Jan. 12, 2017  New research undertaken by ... office of the future.  1,000 participants were simply asked which ... months which we may consider standard issue.  Insights on what ... 2017 were also gathered from futurists and industry leaders including ... James Canton .  Some of ...
(Date:1/11/2017)... Intoxalock, a leading ignition interlock provider, has ... patent-pending calibration device. With this new technology, Intoxalock is ... data logs and process repairs at service center locations, ... drunk driving through the application of cutting-edge technologies is ... also for the customer who can get back on ...
Breaking Biology News(10 mins):